D267N
Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorialAsp→Asn p267 N-term AM=0.11 ddg=+0.77 pLDDT=31. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.
Interactive 3D Structure
Bond changes · DynaMut2 interaction analysis
| Interaction type | Wild-type partner | Mutant partner | Status |
|---|---|---|---|
| Hydrogen bond | L265 | L265 | Preserved |
| Polar contact | L265 | L265 | Preserved |
| Van der Waals | L265 | — | Lost |
Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.
Computational Predictions
- pLDDT 31.11 below 70
The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.
Do not rank this value against a variant from a different region on ΔΔG alone.
Clinical Evidence
Observed in the general population.
ClinVar classifies this variant as Conflicting classifications of pathogenicity for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Cataract 41 (autosomal dominant, OMIM 116400). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.
- Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
- Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
- Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
- WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
- Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
Not attributable to this variant: Lymphedema — 4p16.3 contiguous-gene/CNV submissions.
- Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
- Also submitted under Lymphedema — 4p16.3 contiguous-gene/CNV submissions, not attributable to this coding change.
- Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
- Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.
Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.
Highest in Amish: AF 0.219% (2 of 912 alleles), 5.3x the global figure. The global AF describes the general population, not the at-risk group.
No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.
| Ancestry group | Allele freq. | AC / AN | Hom. | Carrier est. |
|---|---|---|---|---|
| Amish | 0.219% | 2 / 912 | 0 | ~1 in 230 |
| European (non-Finnish) | 0.053% | 628 / 1,180,032 | 0 | ~1 in 940 |
| Remaining individuals | 0.029% | 18 / 62,472 | 0 | ~1 in 1740 |
| African / African American | 0.0093% | 7 / 74,928 | 0 | ~1 in 5350 |
| Admixed American | 0.0083% | 5 / 60,016 | 0 | ~1 in 6000 |
| East Asian | 0.0067% | 3 / 44,892 | 0 | ~1 in 7480 |
| Finnish | 0.0032% | 2 / 63,218 | 0 | ~1 in 15800 |
Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.
Structural Context
Position analysis: ASP268 (2.5 Å — adjacent existing D), GLN266 (2.5 Å), LEU265 (4.2 Å). pLDDT 31 deep IDR. DynaMut2 untrustworthy. The Atlas's neighbor extraction surfaces this variant's contacts.
Druggability Assessment
Why this matters
Feed this card to Wolfram Intelligence
Download the D267N PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.